By Dr. Shweta Agarwal, MBBS, DGO Medically reviewed by Dr. Shweta Agarwal, MBBS, DGO Last updated: June 2026
Information on this page is educational and does not replace a medical consultation. Outcomes depend on individual clinical factors.
Aansh Hospital & IVF Center is a government-registered Level-2 ART clinic (Reg. No. MH/AC/2024/15441/L2/Chandrapur/132), part of a growing chain of fertility centers across Vidarbha and northern Telangana, with our headquarters and in-house embryology lab in Chandrapur. Our ART registration covers both IUI and IVF treatment. This page does not walk through the mechanics of each procedure step by step — the IUI treatment page and IVF treatment page do that thoroughly. What this page addresses is the question couples ask us most often in a first consultation: which one do we actually need?
"IVF ke badle pehle IUI try karna chahiye kya?" — this is one of the most common questions I hear across both my Chandrapur and Nagpur clinics, in Marathi, Hindi, and English, from couples at every stage of their fertility journey. The answer is never the same twice, because it depends on the individual clinical picture. What follows is the framework I use to think through that question with every couple.
What is the core difference between IUI and IVF — in one line each?
IUI (intrauterine insemination) places a prepared sperm sample directly into the uterus at the time of ovulation; fertilisation then happens inside the body, inside the fallopian tube. IVF (in vitro fertilisation) retrieves eggs from the ovaries, fertilises them with sperm in our embryology laboratory, and transfers the resulting embryo directly into the uterus — bypassing the tubes entirely.
This single difference — fertilisation inside the body versus outside, with or without the fallopian tubes in the picture — is the key to understanding when each is appropriate. IUI requires functioning tubes, at least on one side, and sperm capable of completing the journey. IVF needs neither: it removes both variables from the equation. Everything else in the decision framework flows from this.
IUI is simpler, less expensive, and less invasive — it does not involve egg retrieval, sedation, or laboratory fertilisation. IVF is more involved but reaches parts of the infertility picture that IUI cannot address. Neither is inherently "stronger" or "better" in the abstract; the right choice is the one that matches your diagnosis. See the IVF cost & 0% EMI page for a qualitative cost comparison when that factor enters the discussion.
Does tubal status settle the question immediately?
For tubal-factor infertility, yes — tubal status is the most decisive single factor. IUI places sperm inside the uterus; for fertilisation to occur, that sperm must still travel through a fallopian tube to reach the egg. If both tubes are blocked or absent, IUI cannot work by any mechanism — the sperm have nowhere to go. IVF bypasses the tubes entirely: eggs are retrieved directly from the follicles, fertilised in the lab, and the resulting embryo is transferred into the uterine cavity. Tubal patency is simply not a requirement.
For IUI to be appropriate, at least one fallopian tube must be patent — open and structurally functional. This is typically confirmed by hysterosalpingography (HSG) or a similar tubal assessment before IUI is recommended. When both tubes are blocked (bilateral tubal occlusion), IVF is the only medically reasonable pathway for a biological pregnancy.
When one tube is patent and one is blocked, IUI may still be considered in selected cases — but the reduction in functional capacity matters clinically, and IVF is often the more efficient choice. This is a case where the full picture — age, ovarian reserve, duration of infertility — shapes the final call.
How much does sperm quality influence the decision?
Sperm quality is the second major decision driver, and the level of abnormality matters greatly. A semen analysis that shows mildly reduced sperm count or motility — with at least several million total motile sperm available after washing — is generally compatible with IUI. The sperm are placed closer to the tubes, reducing the distance they must cover, and this alone is often enough to overcome mild deficits.
Moderate male factor, depending on the absolute numbers, sits in a grey zone. The question is whether there are genuinely enough motile sperm, after preparation, to give IUI a reasonable chance — or whether ICSI (intracytoplasmic sperm injection, used as part of IVF) is the more appropriate route from the outset.
Severe male factor — very low sperm count (severe oligospermia), very poor motility, or surgically retrieved sperm — requires IVF with ICSI, in which a single selected sperm is injected directly into each egg. IUI is not medically appropriate for severe male-factor infertility: the sperm parameters are too poor for the natural-fertilisation mechanism that IUI depends on. Sending a couple through multiple IUI cycles in this situation delays effective treatment without a realistic clinical basis.
The sperm threshold for IUI suitability is not a single number that applies universally — it depends on the parameters as a set. If you have a semen analysis result and are unsure where it sits, a fertility consultation or a review by Dr. Shweta Agarwal will give you a clear answer.
What role does female age and ovarian reserve play?
Female age and ovarian reserve are the most important predictors of per-cycle outcomes with any fertility treatment, and they are central to the IVF-vs-IUI decision. This is not about urgency pressure; it is a biological reality that shapes how many treatment cycles a couple can afford — in both time and cost — before escalating.
For a woman under 35 with a normal AMH, normal antral follicle count, and a diagnosis that suits IUI (open tubes, mild male factor or unexplained infertility), a stepwise approach — attempting IUI first for a defined number of cycles — is clinically reasonable. There is time, and the ovarian reserve available for IVF, if needed later, will remain adequate.
As female age increases beyond 35, and more so beyond 38, this calculation shifts. Ovarian reserve typically declines with age, and the window for attempting multiple IUI cycles before escalating narrows. In women over 38 with any significant contributing factor (even mild), or in women of any age with a markedly low AMH or low antral follicle count, starting directly with IVF is often the more efficient recommendation — not because IUI is categorically wrong, but because the time spent on IUI cycles that are unlikely to succeed represents a loss of the ovarian reserve that is better used in an IVF cycle.
Low ovarian reserve is itself a direct IVF indication: IVF allows the available eggs to be retrieved and fertilised together, maximising the yield from a diminished reserve. IUI, with its reliance on natural ovulation or mild stimulation, typically produces only one or two eggs — not enough to compensate when reserve is limited.
Rather than a single universal cutoff, the decision is based on your individual AMH and antral follicle count results reviewed alongside your age and clinical history during consultation.
How does a diagnosis of endometriosis affect the choice?
Endometriosis — the presence of endometrial-like tissue outside the uterus — has a nuanced relationship with IUI and IVF recommendations that depends heavily on its stage and location. For more on the condition itself, see the endometriosis conditions page.
In mild endometriosis (Stage I–II), where the tubes and ovaries are not structurally affected, IUI combined with ovarian stimulation remains a reasonable first-line option for many patients, particularly in younger women with adequate ovarian reserve. The tubes are open, and the mild peritoneal-factor effect, while real, does not eliminate IUI from the picture.
In moderate to severe endometriosis (Stage III–IV), the picture changes significantly. Endometriomas on the ovaries reduce accessible ovarian reserve. Tubo-ovarian adhesions can affect tubal patency and function. Distorted pelvic anatomy reduces the likelihood that IUI — which still depends on the fallopian tube for fertilisation — will be effective. For this group, IVF is typically the better-supported recommendation. It bypasses the tubes, allows direct control over fertilisation in the laboratory, and gives the embryologist the ability to select the most viable embryos for transfer.
There is also a practical consideration: endometriosis-related ovarian reserve reduction means that time matters. Spending multiple cycles on IUI in a patient with moderate-to-severe endometriosis may not be in her best clinical interest.
What is unexplained infertility, and does IUI work for it?
Unexplained infertility is the clinical finding of no identifiable cause after a standard diagnostic workup — normal tubes, normal semen analysis, normal ovarian reserve, normal uterine cavity. It accounts for a meaningful proportion of couples presenting for fertility treatment.
For unexplained infertility, IUI combined with controlled ovarian stimulation is a well-established first-line treatment. The reasoning is straightforward: the diagnosis is "we don't know what's preventing conception with natural intercourse," and IUI addresses several of the possible unidentified barriers — cervical mucus quality, sperm transport efficiency, timing of insemination relative to ovulation — without requiring the more invasive egg-retrieval procedure that IVF involves.
IVF, however, provides something IUI cannot: information. When eggs are retrieved and fertilisation is attempted in the laboratory, the embryologist can observe whether fertilisation actually occurs, how embryos develop, and whether there is a problem at the fertilisation or early-development stage that was previously invisible. For this reason, IVF can be both diagnostic and therapeutic for unexplained infertility — it may reveal a hidden fertilisation problem that neither the semen analysis nor any non-invasive test detected.
Current evidence supports attempting IUI for 3–6 cycles in suitable candidates before escalating to IVF. If unexplained infertility persists after that number of attempts, IVF is the logical and well-supported next step.
When is IUI genuinely the right first-line choice?
IUI is a well-evidenced, appropriate first-line treatment — not a consolation prize before IVF — in the following clinical profile:
- At least one patent fallopian tube, confirmed on imaging
- Mild to moderate male factor: reduced sperm count or motility, but enough total motile sperm after washing to give IUI a reasonable basis
- Unexplained infertility in a couple who have been trying for 12 months (or 6 months if the woman is over 35) with otherwise normal workup
- Ovulation disorders including PCOS, where stimulation can produce one or two follicles and IUI is timed precisely to ovulation
- Cervical-factor infertility, where sperm penetration through cervical mucus is the likely barrier
- Normal or near-normal ovarian reserve, with female age below 38, where a stepwise approach does not sacrifice meaningful time
For these couples, IUI offers a realistic clinical pathway, is substantially less expensive and less invasive than IVF, and — if it does not succeed after the recommended number of cycles — does not preclude moving to IVF at that point. The "start simple, escalate if needed" logic is clinically sound here.
A note on cost: IUI costs are substantially lower per cycle than IVF. For couples with an appropriate IUI-compatible diagnosis, this matters — attempting IUI first is a medically reasonable and cost-conscious decision. For couples with a diagnosis that makes IVF necessary, proceeding directly saves the time and cost of IUI cycles that are unlikely to succeed. The costs and EMI page covers both options.
When should we go straight to IVF without trying IUI first?
IVF as the recommended first-line treatment — bypassing IUI — is appropriate in the following situations:
Bilateral tubal occlusion. Both tubes are blocked; IUI has no mechanism by which it could result in pregnancy.
Severe male factor infertility. Severe oligospermia, very poor motility, or surgically retrieved sperm (PESA/TESE/micro-TESE) require ICSI, which is performed as part of IVF. IUI is not appropriate.
Low ovarian reserve or significantly reduced AMH. Maximising the use of available eggs requires IVF; IUI with mild stimulation typically yields only one egg, which is not efficient when reserve is already limited.
Moderate to severe endometriosis. Tubo-ovarian disease, endometriomas affecting reserve, or pelvic adhesions make IUI significantly less likely to succeed and IVF the medically justified route.
Female age over 38 with any significant contributing factor. The time-efficiency of going directly to IVF outweighs the cost advantage of IUI in this group.
Prior failed IUI cycles (typically 3–6). This is the most common escalation scenario: couples who had an IUI-compatible diagnosis, attempted the recommended number of cycles, and did not conceive. IVF is the evidence-based next step.
Recurrent pregnancy loss or known uterine factor requiring PGT. When preimplantation genetic testing (PGT) is clinically indicated — to screen embryos before transfer — IVF is the procedure within which PGT is performed.
In practice, a significant proportion of couples presenting to a fertility clinic are already past the IUI threshold. Recognising that quickly matters — not to rush anyone, but because spending months on IUI when IVF is the correct treatment has real costs in time, emotional energy, and, for older women, ovarian reserve.
How is the decision actually made at Aansh — what does the consultation look like?
The IVF-vs-IUI decision at Aansh is made after a structured first consultation and a targeted diagnostic workup, not before it. No recommendation is made based on age alone or on a single test result.
The typical workup that informs this decision includes:
- Semen analysis — WHO 2021 parameters; determines sperm suitability for IUI vs ICSI/IVF
- Transvaginal ultrasound — antral follicle count, ovarian morphology, uterine cavity
- AMH (anti-Müllerian hormone) — the most reliable single marker of ovarian reserve
- Hormone profile — FSH, LH, oestradiol on Day 2–3, thyroid function
- Tubal assessment — HSG, HyCoSy, or laparoscopy as clinically indicated
Together, these results — mapped against your age, duration of infertility, and any prior treatment history — give the complete clinical picture that the recommendation is based on. Dr. Shweta Agarwal discusses this with you in detail, in Marathi, Hindi, or English, before any treatment decision is made. Our fertility assessment page describes the workup, and the embryology side of the picture is led by Aayush Agarwal, Ph.D., our senior clinical embryologist.
If you have already had an infertility workup elsewhere and want a second look at the recommendation, you are welcome to bring your reports. Our free second opinion service is specifically designed for couples who want an independent read on whether the proposed treatment path is right for them — before committing.
To discuss your situation directly: WhatsApp or call +91 80056 85160.